Tees firm’s new pharmaceutical manufacturing partnership

Teesside-headquartered CPI has signed partnership agreements with Siemens, Perceptive Engineering
and Process Systems Enterprise to form part of a collaboration for the Medicines Manufacturing
Innovation Centre

The partnership agreements will help strengthen the UK’s position as a global leader in pharmaceutical
manufacturing through the development of continuous manufacturing innovations.
Each partner will contribute to the development of a digital manufacturing solution, which will help the
pharmaceutical industry as it moves towards smaller batches of more personalised medicines that
require faster and more efficient manufacture.

Siemens is a global leader in process automation and will provide both hardware and software to
enhance the control of pharmaceutical manufacturing processes. The application of Siemens’ leading-
edge digitalisation technologies will connect the physical and digital worlds and provide the real-time
information necessary for rapid decision making in a secure manner.

Innovation partner Perceptive Engineering will utilise its fully integrated software platform, PharmaMV,
to enable the generation of advanced process control models for optimised continuous manufacturing.
Rather than simply reacting to a set of data points for in-process control, the PharmaMV platform
adapts manufacturing process parameters in response to predictions, ensuring tighter manufacturing
specifications can be achieved and quality information is generated in real-time. These approaches also
enable the future application of technologies such as machine learning and artificial intelligence to
pharmaceutical processing.

PSE is the leading supplier of advanced process modelling (APM) software and will utilise predictive
process modelling to increase research and development efficiency, reduce tech transfer risk and
develop more robust control strategies.

Through use of mechanistic models for continuous drug manufacture in PSE’s gPROMS
FormulatedProducts platform, the industry is able to move away from a design-make-test cycle and
toward a ‘predict first’ model. By reordering the R&D paradigm, more design activities can be

undertaken before committing material, which will result in fast, sustainable and cost-effective
manufacturing process development.

By connecting real-time information, data modelling and advanced process control, they will be able to
forge a clear pathway to faster, cheaper and more sustainable continuous medicines manufacturing.
The Medicines Manufacturing Innovation Centre is a collaboration between CPI, the University of
Strathclyde and founding industry partners, GSK and AstraZeneca with funding provided by Scottish
Enterprise and UK Research and Innovation.

The partnership agreements will help the Medicines Manufacturing Innovation Centre achieve its
flagship Grand Challenge projects. Bringing together three technologies for advancing continuous
manufacturing will help fulfil Grand Challenge 1 and its aim to explore how oral solid dosage medicines
can be produced more robustly and efficiently.

The contribution by Siemens will also support Grand Challenge 2 and its focus on the faster delivery of
medicines to patients through adaptive clinical trial supply.

Mark Higham, general manager, process automation at Siemens Digital Industries GB & Ireland, said:
“We are delighted to be part of such a forward-thinking, innovative collaboration with Perceptive
Engineering, PSE and the Medicines Manufacturing Innovation Centre. We look forward to unlocking
the power of digitalisation to achieve continuous improvement and efficiency in pharmaceutical
manufacturing in the UK.”

Dave Tudor, managing director of the Medicines Manufacturing Innovation Centre, Biologics & Quality
at Wilton Centre-headquartered CPI, said: “I am delighted that Siemens, Perceptive Engineering and PSE
will be joining the Medicines Manufacturing Innovation Centre.

“Combining the specialised skills, expertise and experience of all three companies will be critical for
developing disruptive technologies that will accelerate the delivery of a more agile and responsive
pharmaceutical supply chain.”

CPI works with partners to translate inventions into products and processes that enhance health and
wellbeing, protect and improve our environment and increase productivity across industries.
With a deep understanding of technology fore-sighting, innovation processes and funding, outstanding
technical expertise and industry-relevant assets, CPI enable the accelerated development of
transformational products and processes that have the potential to disrupt and revolutionise markets.